CPC A61K 31/138 (2013.01) [A61P 35/04 (2018.01)] | 12 Claims |
1. A method of treatment of von Hippel-Lindau disease in a patient comprising administering to said patient a therapeutically effective amount of a selective antagonist of the B2-adrenergic receptor selected from a compound of formula (II)
or a pharmaceutically acceptable acid-addition salt thereof, and
wherein said patient has a heterozygous germline pathogenic von Hippel-Lindau disease variant.
|